[1]
|
Davies, L. and Welch, H. (2014) Current Thyroid Cancer Trends in the United States. JAMA Otolaryngology-Head & Neck Surgery, 140, 317-322. https://doi.org/10.1001/jamaoto.2014.1
|
[2]
|
Benhamiche, A.-M., Faivre, C., Minello, A., et al. (1998) Time Trends and Age-Period-Cohort Effects on the Incidence of Primary Liver Cancer in a Well-Defined French Population: 1976-1995. Journal of Hepatology, 29, 802-806. https://doi.org/10.1016/S0168-8278(98)80262-6
|
[3]
|
Davies, L. and Welch, H. (2006) Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. The Journal of the American Medical Association, 295, 2164-2167. https://doi.org/10.1001/jama.295.18.2164
|
[4]
|
Oh, C.-M., Jung, K.-W., Won, Y.-J., et al. (2015) Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 47, 362-369. https://doi.org/10.4143/crt.2014.110
|
[5]
|
Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al. (2006) Survival and Death Causes in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism, 91, 313-319. https://doi.org/10.1210/jc.2005-1322
|
[6]
|
Cooper, D.S., Doherty, G.M., Haugen, B.R., et al. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 16, 109-142. https://doi.org/10.1089/thy.2006.16.109
|
[7]
|
Pitoia, F., Bueno, F., Urciuoli, C., et al. (2013) Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems. Thyroid, 23, 1401-1407. https://doi.org/10.1089/thy.2013.0011
|
[8]
|
Vaisman, F., Momesso, D., Bulzico, D.A., et al. (2012) Spontaneous Remission in Thyroid Cancer Patients after Biochemical Incomplete Response to Initial Therapy. Clinical Endocrinology, 77, 132-138. https://doi.org/10.1111/j.1365-2265.2012.04342.x
|
[9]
|
Jung, C.K., Little, M.P., Lubin, J.H., et al. (2014) The Increase in Thyroid Cancer Incidence during the Last Four Decades Is Accompanied by a High Frequency of BRAF Mutations and a Sharp Increase in RAS Mutations. Journal of Clinical Endocrinology & Metabolism, 99, E276-E285. https://doi.org/10.1210/jc.2013-2503
|
[10]
|
Aschebrook-Kilfoy, B., Kaplan, E.L., Chiu, B.C.-H., et al. (2013) The Acceleration in Papillary Thyroid Cancer Incidence Rates is Similar Among Racial and Ethnic Groups in the United States. Annals of Surgical Oncology, 20, 2746-2753. https://doi.org/10.1245/s10434-013-2892-y
|
[11]
|
Husson, O., Haak, H.R., van Steenbergen, L.N., et al. (2013) Rising Incidence, No Change in Survival and Decreasing Mortality from Thyroid Cancer in The Netherlands Since 1989. Endocrine-Related Cancer, 20, 263-271. https://doi.org/10.1530/ERC-12-0336
|
[12]
|
Davies, H., Bignell, G.R., Cox, C., et al. (2002) Mutations of the BRAF Gene in Human Cancer. Nature, 417, 949-954. https://doi.org/10.1038/nature00766
|
[13]
|
Xing, M. (2005) BRAF Mutation in Thyroid Cancer.. Endocrine-Related Cancer, 12, 245-262. https://doi.org/10.1677/erc.1.0978
|
[14]
|
Nucera, C., Porrello, A., Antonello, Z.A., et al. (2010) B-RafV600E and Thrombospondin-1 Promote Thyroid Cancer Progression. Proceedings of the National Academy of Sciences, 107, 10649-10654. https://doi.org/10.1073/pnas.1004934107
|
[15]
|
Romei, C., Fugazzola, L., Puxeddu, E., et al. (2012) Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. The Journal of Clinical Endocrinology & Metabolism, 97, E1758-E1765. https://doi.org/10.1210/jc.2012-1269
|
[16]
|
Mathur, A., Moses, W., Rahbari, R., et al. (2011) Higher Rate of BRAF Mutation in Papillary Thyroid Cancer over Time. Cancer, 117, 4390-4395. https://doi.org/10.1002/cncr.26072
|
[17]
|
Lee, J.-H., Lee, E.-S. and Kim, Y.-S. (2007) Clinicopathologic Significance of BRAF V600E Mutation in Papillary Carcinomas of the Thyroid. Cancer, 110, 38-46. https://doi.org/10.1002/cncr.22754
|
[18]
|
Kim, Y.H., Yim, H., Lee, Y.-H., et al. (2016) Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens. Journal of Pathology and Translational Medicine, 50, 58-66. https://doi.org/10.4132/jptm.2015.10.10
|
[19]
|
Conzo, G., Avenia, N., Ansaldo, G.L., Calò, P., De Palma, M., et al. (2017) Surgical Treatment of Thyroid Follicular Neoplasms: Results of a Retrospective Analysis of a Large Clinical Series. Endocrine, 55, 530-538. https://doi.org/10.1007/s12020-016-0953-2
|
[20]
|
Marotta, V., Sciammarella, C., Capasso, M., Testori, A., Pivonello, C., et al. (2017) Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism, 102, 661-671.
|
[21]
|
Wan, P.T.C., Garnett, M.J., Roe, S.M., et al. (2004) Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 116, 855-867. https://doi.org/10.1016/S0092-8674(04)00215-6
|
[22]
|
Elisei, R., Ugolini, C., Viola, D., et al. (2008) BRAF(V600E) Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. Journal of Clinical Endocrinology & Metabolism, 93, 3943-3949. https://doi.org/10.1210/jc.2008-0607
|
[23]
|
Gear, H., Williams, H., Kemp, E.G., et al. (2004) BRAF Mutations in Conjunctival Melanoma. Investigative Ophthalmology & Visual Science, 45, 2484-2488. https://doi.org/10.1167/iovs.04-0093
|
[24]
|
Benlloch, S., Payá, A., Alenda, C., et al. (2006) Detection of BRAF V600E Mutation in Colorectal Cancer. The Journal of Molecular Diagnostics, 8, 540-543. https://doi.org/10.2353/jmoldx.2006.060070
|
[25]
|
Chapman, P.B., Hauschild, A., Robert, C., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. The New England Journal of Medicine, 364, 2507-2516. https://doi.org/10.1056/NEJMoa1103782
|
[26]
|
Dietrich, S., Glimm Andrulis, H., et al. (2012) BRAF Inhibition in Refractory Hairy-Cell Leukemia. The New England Journal of Medicine, 366, 2038-2040. https://doi.org/10.1056/NEJMc1202124
|
[27]
|
Nehs, M.A., Nucera, C., Nagarkatti, S.S., et al. (2012) Late Intervention with Anti-BRAF(V600E) Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer. Endocrinology, 153, 985-994. https://doi.org/10.1210/en.2011-1519
|
[28]
|
Schwartz, G.K., Robertson, S., Shen, A., et al. (2009) A Phase I Study of XL281, a Selective Oral RAF Kinase Inhibitor, in Patients (Pts) with Advanced Solid Tumors. Journal of Clinical Oncology, 27, 3513-3513.
|
[29]
|
Moses, W., Weng, J., Sansano, I., et al. (2010) Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-Needle Aspiration Biopsy. World Journal of Surgery, 34, 2589-2594. https://doi.org/10.1007/s00268-010-0720-0
|
[30]
|
Mathur, A., Weng, J., Moses, W., et al. (2010) A Prospective Study Evaluating the Accuracy of Using Combined Clinical Factors and Candidate Diagnostic Markers to Refine the Accuracy of Thyroid Fine Needle Aspiration Biopsy. Surgery, 148, 1170-1177. https://doi.org/10.1016/j.surg.2010.09.025
|
[31]
|
Kim, T.H., Park, Y.J., Lim, J.A., et al. (2012) The Association of the BRAF(V600E) Mutation with Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer: A Meta-Analysis. Cancer, 118, 1764-1773. https://doi.org/10.1002/cncr.26500
|
[32]
|
Tufano, R.P., Teixeira, G.V., Bishop, J., et al. (2012) BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 91, 274-286. https://doi.org/10.1097/MD.0b013e31826a9c71
|
[33]
|
Gray-Schopfer, V., Wellbrock, C. and Marais, R. (2007) Melanoma Biology and New Targeted Therapy. Nature, 445, 851-857. https://doi.org/10.1038/nature05661
|
[34]
|
Hong, T.L., et al. (2018) Relationship between BRAF(V600E) Gene Mutations and Clinicopathological Factors in 192 Thyroid Papillary Carcinomas. Journal of Xinjiang Medical University, No. 2.
|
[35]
|
Xu, H.W., et al. (2017) Relationship between BRAFV600E Gene Mutation and Central Lymph Node Metastasis in Cervical Lymph Node-Negative Thyroid Papillary Microcarcinoma. CJV, 17, 1277-1281.
|
[36]
|
Jin, W.D., et al. (2017) Detection of BRAFV600E Mutation in Papillary Thyroid Carcinoma Based on ARMS Method. Chinese Journal of Otorhinolaryngology Base, 24, 71-75.
|